Candel Therapeutics launches Phase 3 AURORA trial of CAN-2409 combo in advanced NSCLC

Candel Therapeutics, Inc.

Candel Therapeutics, Inc.

CADL

0.00
  • Candel Therapeutics launched the global pivotal Phase 3 AURORA trial of CAN-2409 with valacyclovir alongside continued pembrolizumab in metastatic non-squamous NSCLC.
  • Study targets patients whose disease progressed despite prior pembrolizumab and platinum chemotherapy, comparing the regimen against standard docetaxel.
  • Trial outcomes will be reported in the future; prior Phase 2 results have already been presented and supported moving into Phase 3.
  • Earlier data signaled longer survival for some patients with limited options, supporting a potential new post-checkpoint treatment approach.
  • Enrollment is planned across about 150 sites worldwide with overall survival as the primary endpoint.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300805PRIMZONEFULLFEED9754484) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.